Effects of silymarin supplementation on liver and kidney functions: A systematic review and dose–response meta‐analysis

Fuente: Wiley Open Access
Enregistré dans:
Détails bibliographiques
Auteurs principaux: Shooka Mohammadi, Damoon Ashtary‐Larky, Omid Asbaghi, Vida Farrokhi, Yasaman Jadidi, Fatemeh Mofidi, Mehrnaz Mohammadian, Reza Afrisham
Format: Artículo Open Access
Publié: Wiley 2024
Sujets:
Accès en ligne:
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
_version_ 1867011272014299136
author Shooka Mohammadi
Damoon Ashtary‐Larky
Omid Asbaghi
Vida Farrokhi
Yasaman Jadidi
Fatemeh Mofidi
Mehrnaz Mohammadian
Reza Afrisham
author_facet Shooka Mohammadi
Damoon Ashtary‐Larky
Omid Asbaghi
Vida Farrokhi
Yasaman Jadidi
Fatemeh Mofidi
Mehrnaz Mohammadian
Reza Afrisham
Shooka Mohammadi
Damoon Ashtary‐Larky
Omid Asbaghi
Vida Farrokhi
Yasaman Jadidi
Fatemeh Mofidi
Mehrnaz Mohammadian
Reza Afrisham
collection Wiley Open Access
contents Effects of silymarin supplementation on liver and kidney functions: A systematic review and dose–response meta‐analysis Shooka Mohammadi Damoon Ashtary‐Larky Omid Asbaghi Vida Farrokhi Yasaman Jadidi Fatemeh Mofidi Mehrnaz Mohammadian Reza Afrisham Phytotherapy Research AbstractIt is suggested that supplementation with silymarin (SIL) has beneficial impacts on kidney and liver functions. This systematic review and dose–response meta‐analysis assessed the impact of SIL administration on certain hepatic, renal, and oxidative stress markers. A systematic search was conducted in various databases to identify relevant trials published until January 2023. Randomized controlled trials (RCTs) that evaluated the effects of SIL on kidney and liver markers were included. A random‐effects model was used for the analysis and 41 RCTs were included. The pooled results indicated that SIL supplementation led to a significant reduction in serum levels of alkaline phosphatase, alanine transaminase, creatinine, and aspartate aminotransferase, along with a substantial elevation in serum glutathione in the SIL‐treated group compared to their untreated counterparts. In addition, there was a nonsignificant decrease in serum levels of gamma‐glutamyl transferase, malondialdehyde (MDA), total bilirubin, albumin (Alb), total antioxidant capacity, and blood urea nitrogen. Sub‐group analyses revealed a considerable decline in MDA and Alb serum values among SIL‐treated participants with liver disease in trials with a longer duration (≥12 weeks). These findings suggest that SIL may ameliorate certain liver markers with potential hepatoprotective effects, specifically with long‐term and high‐dose supplementation. However, its nephroprotective effects and impact on oxidative stress markers were not observed. Additional high‐quality RCTs with longer durations are required to determine the clinical efficacy of SIL supplementation on renal and oxidative stress markers. 10.1002/ptr.8173 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1002/ptr.8173
format Artículo Open Access
id wiley_oa_10_1002_ptr_8173
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2024
publisher Wiley
record_format wiley_oa
spellingShingle Effects of silymarin supplementation on liver and kidney functions: A systematic review and dose–response meta‐analysis
Shooka Mohammadi
Damoon Ashtary‐Larky
Omid Asbaghi
Vida Farrokhi
Yasaman Jadidi
Fatemeh Mofidi
Mehrnaz Mohammadian
Reza Afrisham
Phytotherapy Research
Effects of silymarin supplementation on liver and kidney functions: A systematic review and dose–response meta‐analysis Shooka Mohammadi Damoon Ashtary‐Larky Omid Asbaghi Vida Farrokhi Yasaman Jadidi Fatemeh Mofidi Mehrnaz Mohammadian Reza Afrisham Phytotherapy Research AbstractIt is suggested that supplementation with silymarin (SIL) has beneficial impacts on kidney and liver functions. This systematic review and dose–response meta‐analysis assessed the impact of SIL administration on certain hepatic, renal, and oxidative stress markers. A systematic search was conducted in various databases to identify relevant trials published until January 2023. Randomized controlled trials (RCTs) that evaluated the effects of SIL on kidney and liver markers were included. A random‐effects model was used for the analysis and 41 RCTs were included. The pooled results indicated that SIL supplementation led to a significant reduction in serum levels of alkaline phosphatase, alanine transaminase, creatinine, and aspartate aminotransferase, along with a substantial elevation in serum glutathione in the SIL‐treated group compared to their untreated counterparts. In addition, there was a nonsignificant decrease in serum levels of gamma‐glutamyl transferase, malondialdehyde (MDA), total bilirubin, albumin (Alb), total antioxidant capacity, and blood urea nitrogen. Sub‐group analyses revealed a considerable decline in MDA and Alb serum values among SIL‐treated participants with liver disease in trials with a longer duration (≥12 weeks). These findings suggest that SIL may ameliorate certain liver markers with potential hepatoprotective effects, specifically with long‐term and high‐dose supplementation. However, its nephroprotective effects and impact on oxidative stress markers were not observed. Additional high‐quality RCTs with longer durations are required to determine the clinical efficacy of SIL supplementation on renal and oxidative stress markers. 10.1002/ptr.8173 http://onlinelibrary.wiley.com/termsAndConditions#vor
title Effects of silymarin supplementation on liver and kidney functions: A systematic review and dose–response meta‐analysis
topic Phytotherapy Research
url https://onlinelibrary.wiley.com/doi/10.1002/ptr.8173